New combo therapy offers hope for advanced cervical cancer patients
NCT ID NCT07472153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of immunotherapy drugs (PD-1/PD-L1 inhibitors) with chemotherapy, with or without bevacizumab, in 120 adults with metastatic, persistent, or recurrent cervical cancer. The goal is to see if this approach helps patients live longer and controls the disease. Participants must be between 18 and 75 years old and have a confirmed diagnosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
N.N. Alexandrov National Caner Centre
RECRUITINGMinsk, Lesnoy, 223040, Belarus
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
- Blood test may spot returning cervical cancer before symptoms appear
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- Experimental cell therapy targets multiple cancers in early trial
- Immunotherapy combo shows promise for advanced cervical cancer
- New combo therapy shows promise for Tough-to-Treat cervical cancer